Italia markets close in 3 hours 47 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
160,03+10,32 (+6,89%)
Alla chiusura: 4:00PM EDT

163,40 +3,37 (2,11%)
Preborsa: 7:42AM EDT

Accedi per pubblicare un messaggio.
  • M
    Michael1
    $NVAX conversation
    How about that $MRNA flu vaccine talk guys? How does that make you feel?
  • T
    Titos
    $MRNA conversation
    CNBC Halftime Report Final Trades:
    Joe Terranova: Nvidia $NVDA
    Steve Weiss: Moderna $MRNA
    Liz Young: Invesco Dyn Leisure and Ent $PEJ
    Degas Wright: Amphenol $APH
  • J
    Jimmy
    $MRNA
    “New preclinical data shows variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralizing titers against SARS-CoV-2 variants of concern”
  • J
    JC
    $ABUS conversation
    $ABUS $MRNA Oral Argument in Arbutus LNP Patent Dispute Set for April 9
    The appeals court has scheduled oral argument for Moderna's challenge of an Arbutus LNP patent. The PTAB found that Moderna failed to demonstrate some claims invalid. We think Moderna has an uphill battle for a reversal. Importantly, it remains unclear if this dispute actually matters to Moderna. The Federal Circuit appeals court has scheduled oral argument on 4/9 for one of the three Arbutus LNP patents that Moderna has challenged in inter partes review (IPR). In the challenge of this patent (9,364,435), the Patent Trial and Appeal Board (PTAB) found that Moderna failed to demonstrate that some of the challenged claims are unpatentable. Moderna is seeking to get the PTAB decision on those claims reversed or have the case remanded back to the PTAB for a second look.

    Does this dispute matter with respect to Moderna's COVID-19 vaccine? Based on our review of the Moderna's PhIII protocol and various agency documents, we have seen no evidence that Moderna's LNP has the four components (a cationic lipid, a PEG-based lipid, a phospholipid, and cholesterol) in the percentages required by the Arbutus patents. Although some investors have pointed to preprint articles on the early-stage development of Moderna's vaccine as suggesting that it has the patented percentages, we note two points. First, mgt. has said that those preprint articles do not reflect the actual percentages in Moderna's COVID-19 vaccine. Second, a document from the EMA (here) states that the lipid percentages were modified during the PhIII trial: "the lipid concentrations [of Moderna's vaccine] were slightly modified during manufacture for Phase III." We thus continue to believe that no evidence indicates that Moderna's commercially marketed COVID-19 vaccine literally infringes this Arbutus patent. As we explained in another note (here), though, even if Moderna's LNP does not literally infringe Arbutus's patent, Arbutus could sue Moderna for patent infringement under the doctrine of equivalents, if Moderna's percentages are different from but similar to the patented percentages. Indeed, in a brief that Moderna recently filed in a dispute on another Arbutus patent (Fed. Cir. 20-22329), Moderna said that "there is a substantial risk that Arbutus will sue Moderna for infringement.
    When can we expect any litigation to arise between Moderna and Arbutus? We think that if this patent survives the appeal, if Arbutus will ever sue Moderna on this patent, it will do so shortly after the appeal decision. That is, if Arbutus does not sue Moderna within a few months after an appeal decision upholding the validity of at least one patent claim, we think it will become less and less likely that Arbutus will ever sue Moderna on its LNP patents.

    As an alternative to litigation, we note that after any patent decision upholding the validity of at least one patent claim, Arbutus may seek to settle its disputes with Moderna. In that case, Moderna may have to pay a low-to-mid-single-digit royalty.

    When will the Federal Circuit appeals court likely issue a decision? The Federal Circuit typically takes up to four months to issue a decision after oral argument. Given that the oral argument is scheduled for April 9, that would take us to August 9, 2021. Thus, a decision could be issued shortly after April 9 and up until around mid-August. Will the oral argument be available to the public? Yes. Given the pandemic, the Federal Circuit has made all oral arguments available to the public live.
  • A
    Alex
    $INO conversation
    I just got word, TIME OUT MELLON put his LIFE SAVINGS into INO today . It’s been reported he has BOUGHT 11 shares at $8.46 . WOW! 💰💰💰even bigger news $MRNA ceo falls out of car at Walmart 👀
  • P
    PumpStar (DR. KIM ROCKS!!!!!!)
    $INO conversation
    "INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants" https://www.biorxiv.org/content/10.1101/2021.04.14.439719v1

    EVERYBODY BUY INO SHARES !!!!!!!!!!!!! SKYROCKETING IMMINENT !!!!!!!!!! THANKS, DR: KIM, FOR THE GREAT WORK YOU HAVE DONE !!!!! SPREAD THE WORD ABOUT INO MIRACLE !!!!!!!

    $GME $AMC $NOK $BB $TSLA $MRNA $NIO $DVAX $WORK $NKLA $MSFT $AAPL $SPCE $SRNE
  • J
    JoeMomma
    $BA and $MRNA two best stocks to be holding right now!
  • D
    Derek
    $SLS conversation
    Apparently shorts did not like my blurb about SLS, and how fast it may go up, upon its first FDA approval, which should be happening soon. Why? Because other message boards were looking at it. And there is a very large short position right now. Just remembered that the amount of outstanding shares is very low, which is unheard of before a profitable pharmaceutical company. That means news of an FDA approval will send this flying extraordinarily high, with a split, and have it continue to go up. $MRNA , $CYDY, $PFE
  • C
    CarterMX
    $MRNA conversation
    Moderna co-founder and chairman, Noubar Afeyan, has been selling large blocks of shares...

    through... Flagship Pioneering

    Noubar Afeyan is founder and CEO of Flagship Pioneering (3rd largest shareholder in $MRNA)

    Flagship started with 60 Million $MRNA shares and holds 20 Million shares today...

    It is interesting to see the many companies that Flagship has already started...
    Companies
    www.flagshippioneering.com
  • C
    CashMonday
    $PFE conversation
    $PFE BUYING PRESSURE THE NEXT $MRNA
  • C
    CashMonday
    $PFE conversation
    Pfizer Moderna $PFE $MRNA Pfizer and Moderna could make $32 billion off Covid-19 ...
  • B
    BePositive
    $PFE conversation
    Got the PFE COVID short yesterday, great to read 1st shot 80% effective... $MRNA also another game changer... Also, eyeing ACRX, which has been SO WAY OVERSOLD.... see ACRX is ticking higher, with ACRX 500% based on avg analyst's Price Target!
  • D
    Derek
    $PFE conversation
    $SLS about to move big. Profitable very low shares outstanding, almost to an FDA approval on one of it's phase 3 trials. Other Phase 3 trials in the pipeline.

    Since so few shares, an FDA approval could look something like this. News: SLS driven by wall street to $400.00 a share today with an FDA approval for ... The company announces a 10 to 1 split. Next day: SLS opened at $40.00 a share today as shares continued to soar reaching nearly $100.00 per share at close.

    Yup we have seen other similar movements, but nothing that has so few shares outstanding. Pfizer went similarly on Viagra launch.

    $MRNA also saw huge numbers on its EUA.

    $CYDY will probably see similar results for it's HIV drug, and Covid-19 EUA.
  • G
    GoodToHear
    Inovio Pharmaceuticals, Inc.
    INO any day COVID vaccine news!! ACRX news out, new Board Member $30 Billion in M&A background - ACRX Buyout coming!!! also $PFE ought to Buy either $NVAX or $MRNA
  • M
    Metal Ox
    Ugh. Shocked and disappointed by CNBC article earlier today. Idea is to simply give away USA intellectual property??? So easy for other countries for decades to take advantage of American nobleness. China and other countries must be laughing and waiting to leverage USA gift to become global leaders in mRNA technology. Ugh.

    White House weighs temporarily lifting intellectual property shield on Covid-19 vaccines
    FRI, MAR 26 20215:44 PM EDT
    # The White House is weighing whether to temporarily lift intellectual property protections on Covid-19 vaccines and treatments.
    # The move would allow other countries to replicate existing vaccines.

    $arct, $bntx, $cvac, $mrna, $tbio
  • B
    Baily
    $MRNA conversation
    Going to be a strong year for $MRNA
  • U
    Uptick
    For Baillie Gifford (BG) to buy 11.7% of outstanding shares, $MRNA management told them something BG REALLY liked. A firm does not take that kind of stake without knowing it will be a strong performer. The strong conviction of BG is enough to instill major confidence in my investment here.
  • A
    Axelvento
    $MRNA conversation
    $MRNA
    partnership between Moderna & IBM for vaccine supply chain & distribution is obviously a WIN!
  • G
    GuyGuy
    $ABUS conversation
    Take the A -Bus.... Baby!!
    $ABUS $MRNA Oral Argument in Arbutus LNP Patent Dispute Set for April 9
    The appeals court has scheduled oral argument for Moderna's challenge of an Arbutus LNP patent. The PTAB found that Moderna failed to demonstrate some claims invalid. We think Moderna has an uphill battle for a reversal. Importantly, it remains unclear if this dispute actually matters to Moderna. The Federal Circuit appeals court has scheduled oral argument on 4/9 for one of the three Arbutus LNP patents that Moderna has challenged in inter partes review (IPR). In the challenge of this patent (9,364,435), the Patent Trial and Appeal Board (PTAB) found that Moderna failed to demonstrate that some of the challenged claims are unpatentable. Moderna is seeking to get the PTAB decision on those claims reversed or have the case remanded back to the PTAB for a second look.

    Does this dispute matter with respect to Moderna's COVID-19 vaccine? Based on our review of the Moderna's PhIII protocol and various agency documents, we have seen no evidence that Moderna's LNP has the four components (a cationic lipid, a PEG-based lipid, a phospholipid, and cholesterol) in the percentages required by the Arbutus patents. Although some investors have pointed to preprint articles on the early-stage development of Moderna's vaccine as suggesting that it has the patented percentages, we note two points. First, mgt. has said that those preprint articles do not reflect the actual percentages in Moderna's COVID-19 vaccine. Second, a document from the EMA (here) states that the lipid percentages were modified during the PhIII trial: "the lipid concentrations [of Moderna's vaccine] were slightly modified during manufacture for Phase III." We thus continue to believe that no evidence indicates that Moderna's commercially marketed COVID-19 vaccine literally infringes this Arbutus patent. As we explained in another note (here), though, even if Moderna's LNP does not literally infringe Arbutus's patent, Arbutus could sue Moderna for patent infringement under the doctrine of equivalents, if Moderna's percentages are different from but similar to the patented percentages. Indeed, in a brief that Moderna recently filed in a dispute on another Arbutus patent (Fed. Cir. 20-22329), Moderna said that "there is a substantial risk that Arbutus will sue Moderna for infringement.
    When can we expect any litigation to arise between Moderna and Arbutus? We think that if this patent survives the appeal, if Arbutus will ever sue Moderna on this patent, it will do so shortly after the appeal decision. That is, if Arbutus does not sue Moderna within a few months after an appeal decision upholding the validity of at least one patent claim, we think it will become less and less likely that Arbutus will ever sue Moderna on its LNP patents.

    As an alternative to litigation, we note that after any patent decision upholding the validity of at least one patent claim, Arbutus may seek to settle its disputes with Moderna. In that case, Moderna may have to pay a low-to-mid-single-digit royalty.

    When will the Federal Circuit appeals court likely issue a decision? The Federal Circuit typically takes up to four months to issue a decision after oral argument. Given that the oral argument is scheduled for April 9, that would take us to August 9, 2021. Thus, a decision could be issued shortly after April 9 and up until around mid-August. Will the oral argument be available to the public? Yes. Given the pandemic, the Federal Circuit has made all oral arguments available to the public live.
  • A
    Axelvento
    $MRNA conversation
    $MRNA - not just a COVID19 company; its so much more. Early Ph 1 data of #Cancer vaccine: safe, well-tolerated & shows promising efficacy, shrunk tumor by
    @60
    % in 2 patients who had NOT responded to current standard of care treatment. Very promising. See link below.

    https://twitter.com/stephenLweiss/status/1366825699705815044